Actelion mainly integrates additional innovation into its pipeline through in-licensing, but does not exclude acquisitions should the opportunity arise.

Actelion acquired privately-owned Axovan AG in September 2003, integrating into its pipeline clazosentan, an intravenous endothelin receptor antagonist.

CoTherix Inc.
Actelion completed the acquisition of CoTherix Inc. in March 2007, thereby strengthening its PAH franchise by adding Ventavis® to its product offerings in the United States.

Ceptaris Therapeutics Inc.
Actelion completed the acquisition of CeptarisTherapeutics Inc. in September 2013, thereby adding Valchlor™ to its product portfolio.



Business Development
Actelion Pharmaceuticals Ltd
Gewerbestrasse 16
CH-4123 Allschwil
Tel.: +41 61 565 63 16
Fax: +41 61 565 65 00
Contact us onlineHow to get to us

Drug Safety Coordinator, Global Drug Safety 


"Employees are given great opportunities to get involved in important plans for the business/company, this makes Actelion different."